Activating KRAS mutations are found in more than 20% of all human cancers, including low-grade serous ovarian carcinoma, lung carcinoma, pancreatic cancer, endometrial cancer, and colorectal carcinoma1–6. Here, KRAS is linked to ovarian serous carcinoma.